Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

December 3, 2020

Primary Completion Date

July 30, 2025

Study Completion Date

December 31, 2025

Conditions
Cardiovascular Disease With Mention of ArteriosclerosisElevated CholesterolFamilial Hypercholesterolemia
Interventions
DRUG

lerodalcibep

PCSK9 inhibitor

Trial Locations (12)

2193

Carbohydrate and Lipid Metabolism Research Unit, Johannesburg

7925

Division of Lipidology, Department of Medicine University of Cape Town, Cape Town

12000

Department of Medicine, Hadassah University Hospital, Jerusalem

35040

Ege University Medical School, Izmir

45219

Sterling Research Group, Cincinnati

The Lindner Research Center, Cincinnati

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

49100

Rabin Medical Center, Beilinson Hospital,, Petah Tikva

60201

NorthShore University Health System, Evanston

110002

G.B. Pant Institute of Postgraduate Medical Education & Research, New Delhi

0586

Lipid Clinic, Oslo University Hospital, Oslo

Unknown

Afyonkarahisar Health Sciences University, Afyonkarahisar

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

LIB Therapeutics LLC

INDUSTRY

NCT04798430 - Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction | Biotech Hunter | Biotech Hunter